Adherence to adjuvant endocrine therapy in women with breast cancer

Danilak, Melanie; Chambers, Carole

doi:10.1177/1078155212455939

Cited by 17 publications

(6 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Women who undergo hormonal therapy need to take tamoxifen or aromatase inhibitor orally, on a daily basis for a total of 5 years. However, epidemiological studies based on different databases and different methodologies concluded that adherence and persistence to adjuvant hormonal therapy among breast cancer survivors is suboptimal [16,17,18,19,20,21,22,23]. For example, in line with our rather long term study results, the French National Health Insurance System database reported a discontinuation rate of 39.5% (95% CI 32.9 -47.0) after 3 years of tamoxifen intake [19].…”

Section: Discussionsupporting

confidence: 72%

Adherence in tamoxifen therapy after conversion to a rebate pharmaceutical in breast cancer patients in Germany

Kostev¹,

May²,

Hog³

et al. 2013

View full text Add to dashboard Cite

This analysis underlines an association between the initiation of rebate contracts and a negative impact on the compliance of breast cancer patients on an adjuvant hormonal treatment The impact of rebate contracts on the health of patients and the health care costs should be evaluated in further therapeutic fields through additional research projects. *both authors contributed equally to the manuscript.

show abstract

Section: Discussionsupporting

confidence: 72%

Adherence in tamoxifen therapy after conversion to a rebate pharmaceutical in breast cancer patients in Germany

Kostev¹,

May²,

Hog³

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Women in our study were treated more recently (2005-2010) compared with a timeframe of 2002-2004 in above-cited study [8]. A single-site study performed in 2006 reported similar rates of initiation and persistence [39]. …”

Section: Discussionmentioning

confidence: 92%

Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer

Friese

Pini

et al. 2013

Breast Cancer Res Treat

View full text Add to dashboard Cite

Background Adjuvant endocrine therapy for breast cancer reduces recurrence and improves survival rates. Many patients never start treatment or discontinue prematurely. A better understanding of factors associated with endocrine therapy initiation and persistence could inform practitioners how to support patients. Methods We analyzed data from a longitudinal study of 2,268 women diagnosed with breast cancer and reported to the Metropolitan Detroit and Los Angeles SEER cancer registries in 2005-2007. Patients were surveyed approximately both 9 months and 4 years after diagnosis. At 4-years, patients were asked if they had initiated endocrine therapy, terminated therapy, or were currently taking therapy (defined as persistence). Multivariable logistic regression models examined factors associated with initiation and persistence. Results Of the 743 patients eligible for endocrine therapy, 80 (10.8%) never initiated therapy, 112 (15.1%) started therapy but discontinued prematurely, and 551 (74.2%) continued use at the second time point. Compared with whites, Latinas (OR 2.80, 95% CI 1.08-7.23) and black women (OR 3.63, 95% CI 1.22-10.78) were more likely to initiate therapy. Other factors associated with initiation included worry about recurrence (OR 3.54, 95% CI 1.31 – 9.56) and inadequate information about side effects (OR 0.24, 95% CI 0.10 – 0.55). Factors associated with persistence included two or more medications taken weekly (OR 4.19, 95% CI 2.28-7.68) and increased age (OR 0.98, 95% CI 0.95-0.99). Conclusions Enhanced patient education about potential side effects and the effectiveness of adjuvant endocrine therapy in improving outcomes may improve initiation and persistence rates and optimize breast cancer survival.

show abstract

“…Current treatment strategies focus on surgery, in combination with radiotherapy and chemotherapy. However, overall survival and mortality rates, in particular for late-stage breast cancer patients, remain poor ( 6 ). A deeper understanding of breast cancer tumorigenesis may aid the development of more effective treatment measures.…”

Section: Introductionmentioning

confidence: 99%

A novel method to limit breast cancer stem cells in states of quiescence, proliferation or differentiation: Use of gel stress in combination with stem cell growth factors

et al. 2016

View full text Add to dashboard Cite

The majority of cancer stem cells exist in the G0, or quiescent phase of the cell cycle. However, the cells can escape quiescence following routine radiotherapy and chemotherapy, resulting in tumor recurrence. Presently, achieving the accurate regulation of cancer stem cell growth in order to study a specific state, including the quiescent (mostly G0 or G1 phase), proliferative (mostly S phase) or differential (mostly G2/M phase) states, can be challenging. This makes the determination of cell cycle state-specific characteristics and analysis of potential intervention treatments difficult, particularly for quiescent cells. Breast cancer stem cells were cultured on a soft or hard agar matrix surface in the presence or absence of stem cell growth factors. Cells could be successfully limited in either the quiescent, proliferative or differentiated states. These findings provide a foundation for further study of the cell cycle in breast cancer stem cells.

show abstract

Adherence to adjuvant endocrine therapy in women with breast cancer

Abstract: The majority of patients who were prescribed adjuvant endocrine therapy for breast cancer at the Cross Cancer Institute remained on therapy for at least 2 years and were adherent. Longer follow-up by Cross Cancer Institute practitioners may help decrease discontinuation rates.

Cited by 17 publications

References 21 publications

Adherence in tamoxifen therapy after conversion to a rebate pharmaceutical in breast cancer patients in Germany

Adherence in tamoxifen therapy after conversion to a rebate pharmaceutical in breast cancer patients in Germany

Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer

A novel method to limit breast cancer stem cells in states of quiescence, proliferation or differentiation: Use of gel stress in combination with stem cell growth factors

Contact Info

Product

Resources

About